培美曲塞二钠联合奈达铂治疗老年晚期肺腺癌的临床疗效及安全性观察  

Clinical Observation of Pemetrexed Combined with Nedaplatin in the Treatment of Elderly Patients with Advanced Lung Adenocacinoma

作　　者：凌华晃[1,2] 李涛[1,2] 吴祥成[1,2] 蔡茂德 苏炳光[1,2] 

机构地区：[1]广东省高州市人民医院 [2]广东医学院附属高州医院化疗科,525200

出　　处：《中国全科医学》2013年第21期2506-2508,共3页Chinese General Practice

摘　　要：目的探讨培美曲塞二钠联合奈达铂治疗老年晚期肺腺癌的疗效及安全性。方法选取高州市人民医院化疗科2009年1月—2012年6月收治的老年晚期肺腺癌患者47例,随机数字表法分成对照组20例和观察组27例。对照组采用吉西他滨1 000 mg/m2,静脉滴注第1天,奈达铂80 mg/m2,静脉滴注第1天。观察组采用培美曲塞二钠500 mg/m2,静脉滴注第1天,奈达铂80 mg/m2,静脉滴注第1天,21 d为1个周期。观察两组治疗有效率及毒副作用发生情况。结果观察组有效率为40.7%(11/27),对照组为35.0%(7/20),两组比较差异无统计学意义(χ2=0.0720,P=0.7885);观察组Ⅲ度以上白细胞减少发生率较对照组降低,差异有统计学意义(χ2=4.3649,P=0.0330)。结论培美曲塞二钠联合奈达铂治疗老年晚期肺腺癌疗效肯定,安全性较高,可以在临床中应用。Objective To evaluate the efficacy and safety of pemetrexed combined with nedaplatin in the treatment of elderly patients with advanced lung adenocacinoma.Methods 47 elderly patients with advanced lung adenocacinoma from January 2009 to June 2012 were randomly divided into control group（20 cases） and observation group（27 cases）.The control group was treated by gemcitbine 1 000 mg / m2 combined with nedaplatin 80 mg / m2（d1）,while the observation group was treated by pemetrexed 500 mg / m2 combined with nedaplatin 80 mg / m2（d1）,with 21 days as 1 cycle.The effect rate and toxic and side effect of the two groups were observed.Results There were no significant differences between the two groups in overall response rate〔40.7%（11 /27） in the treatment group vs.35.0%（7 /20） in the control group,χ2 = 0.0720,P = 0.7885〕.But there were significant differences between the two groups in over grade Ⅲ leukocypenia（χ2 = 4.3649,P = 0.0330）.Conclusion Pemetrexed combined with nedaplatin shows good efficacy in the treatment of elderly patients with advanced lung adenocacinoma.The toxicities were not serious and it can be safely used in practice.

关 键 词：肺肿瘤 腺癌 培美曲塞 奈达铂 抗肿瘤联合化疗方案 

分 类 号：R734.2[医药卫生—肿瘤]